NEUROPATHIC PAIN
DR NAEMAH BINTI SHARIFUDDIN
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
INTRODUCTION
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
INTRODUCTION
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
DIAGNOSIS
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
MANAGEMENT
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
DIAGNOSTIC SCREENING TOOLS
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
LANSS PAIN SCALE
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
S-LANSS – patient self score
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
Score of ≥ 4 indicates neuropathic pain
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
Pain DETECT
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
EXAMINATION
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
INVESTIGATIONS
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
Common Neuropathic Pain seen in Primary Care
Condition | Cause |
Diabetic Polyneuropathy (DPN) | Metabolic disease |
Trigeminal neuralgia (TN) | Peripheral nerve compression/ idiopathic |
Post herpetic neuralgia (PHN) | Infection |
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
DIABETIC POLYNEUROPATHY (DPN)
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
DIABETIC POLYNEUROPATHY (DPN) - MANAGEMENT
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
POSTHERPETIC NEURALGIA (PHN)
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
POSTHERPETIC NEURALGIA (PHN) - MANAGEMENT
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
TRIGEMINAL NEURALGIA
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
TRIGEMINAL NEURALGIA
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
TRIGEMINAL NEURALGIA
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
COMPLEX REGIONAL PAIN SYNDROME
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
CASE DISCUSSIONS
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
CASE SCENARIO 1
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
CASE SCENARIO 1
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
DIAGNOSTIC TOOL: DN4 NEUROPATHIC PAIN DIAGNOSTIC QUESTIONNAIRE
4
X
X
X
X
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
CASE SCENARIO 1
DIAGNOSIS?
The goals of management in neuropathic pain are:
Best results with multidisciplinary approach
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
MANAGEMENT
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
DRUG | RECOMMENDED FOR | STARTING DOSE | DOSE TITRATION (IF NECESSARY) | MAXIMUM DOSE | DURATION OF ADEQUATE TRIAL |
ANTICONVULSANT | |||||
Pregabalin | PHN (1st line) DPN (1st line) TN (2nd line) | 150mg/day as 75mg bid | increase to 300mg daily after 3-7 days, then by 150mg/day every 3-7 days as tolerated | 600mg daily (300mg bid | 4 weeks |
Gabapentin | PHN (1st line) DPN (1st line) TN (2nd line) | Day 1, 300mg at bedtime Day 2, 300mg bid Day 3, 300mg tid | increase by 300mg tid every 1-7 days as tolerated | 3,600mg daily (1,200mg tid) | 3-8 weeks for titration plus 2 weeks at maximum tolerated dose |
ANTI DEPRESSANT | |||||
amitriptyline | PHN (1st line) DPN (1st line) TN (2nd line) | 10-25mg daily at bedtime | increase by 10-25mg weekly | up to 50mg | 3 months at maximum tolerated dosage |
nortriptyline, despiramine
| PHN (1st line) DPN (1st line) TN (2nd line) | 10-25mg daily at bedtime | increase by 25mg dly every 3-7 days as tolerated | 150mg dly | 6-8 weeks with at least 2 weeks at maximum tolerated dosage |
duloxetine | DPN (1st line) | 30mg/day | increase to 60mg/day after 1 wk | 60mg twice a day | 4 weeks |
OPIOIDS | |||||
morphine, oxycodone | conditions with mixed nociceptive and neuropathic pain | 10-15mg morphine q4hr or as needed (equianalgesic dosage for other opioid analgesics) | after 1-2 wks convert total dosage to long-acting opioid analgesic and continue short-acting medication as needed | no maximum dosage with careful titration | 4-6 weeks |
tramadol | PHN (2nd line) DPN (2nd line) | 50mg qd or bid | increase by 50-100mg dly in divided doses every 3-7days as tolerated | 400mg OD (100mg QID); 300mg OD in patients >75 years | 4 weeks |
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
OTHER MANAGEMENT
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
CASE SCENARIO 2
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
CASE SCENARIO 2
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
DIAGNOSTIC TOOL: DN4 NEUROPATHIC PAIN DIAGNOSTIC QUESTIONNAIRE
4
X
X
X
X
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
CASE SCENARIO 2
The goals of management in neuropathic pain are:
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
PAIN RELIEF
Other management:
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
DRUG | RECOMMENDED FOR | STARTING DOSE | DOSE TITRATION (IF NECESSARY) | MAXIMUM DOSE | DURATION OF ADEQUATE TRIAL |
ANTICONVULSANT | |||||
Pregabalin | PHN (1st line) DPN (1st line) TN (2nd line) | 150mg/day as 75mg bid | increase to 300mg daily after 3-7 days, then by 150mg/day every 3-7 days as tolerated | 600mg daily (300mg bid | 4 weeks |
Gabapentin | PHN (1st line) DPN (1st line) TN (2nd line) | Day 1, 300mg at bedtime Day 2, 300mg bid Day 3, 300mg tid | increase by 300mg tid every 1-7 days as tolerated | 3,600mg daily (1,200mg tid) | 3-8 weeks for titration plus 2 weeks at maximum tolerated dose |
ANTI DEPRESSANT | |||||
amitriptyline | PHN (1st line) DPN (1st line) TN (2nd line) | 10-25mg daily at bedtime | increase by 10-25mg weekly | up to 50mg | 3 months at maximum tolerated dosage |
nortriptyline, despiramine
| PHN (1st line) DPN (1st line) TN (2nd line) | 10-25mg daily at bedtime | increase by 25mg dly every 3-7 days as tolerated | 150mg dly | 6-8 weeks with at least 2 weeks at maximum tolerated dosage |
duloxetine | DPN (1st line) | 30mg/day | increase to 60mg/day after 1 wk | 60mg twice a day | 4 weeks |
OPIOIDS | |||||
morphine, oxycodone | conditions with mixed nociceptive and neuropathic pain | 10-15mg morphine q4hr or as needed (equianalgesic dosage for other opioid analgesics) | after 1-2 wks convert total dosage to long-acting opioid analgesic and continue short-acting medication as needed | no maximum dosage with careful titration | 4-6 weeks |
tramadol | PHN (2nd line) DPN (2nd line) | 50mg qd or bid | increase by 50-100mg dly in divided doses every 3-7days as tolerated | 400mg OD (100mg QID); 300mg OD in patients >75 years | 4 weeks |
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
PROGRESS OF PATIENT
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
THANK YOU
PAIN FREE PROGRAMME I KEMENTERIAN KESIHATAN MALAYSIA I BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA